




| | | | |
|---------------------------------|--|----------------------------|---------------------------|
| | | EMLc | ATC codes: J04AB01 |
| Indication | Multi-drug resistant Mycobacterium tuberculosis | ICD11 code: ML32.00 | |
| INN | Cycloserine | | |
| Medicine type | Chemical agent | | |
| List type | Complementary (EML) (EMLc) | | |
| Additional notes | The square box applies only to listing of cycloserine on the EML. | | |
| Formulations | Oral > Solid: 250 mg ; 125 mg (EMLc) | | |
| EML status history | First added in 1999 (TRS 895) Changed in 2003 (TRS 920) Changed in 2007 (TRS 950) Changed in 2015 (TRS 994) Changed in 2019 (TRS 1021) Changed in 2021 (TRS 1035) | | |
| Sex | All | | |
| Age | Also recommended for children | | |
| Therapeutic alternatives | terizidone (ATC codes: J04AK03) | | |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  | | |
| Wikipedia | Cycloserine  | | |
| DrugBank | Cycloserine  | | |

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended terizidone be specified as a therapeutic alternative under the square box listing for cycloserine on the EML.

